Formoterol/glycopyrrolate - Pearl Therapeutics

Drug Profile

Formoterol/glycopyrrolate - Pearl Therapeutics

Alternative Names: BEVESPI AEROSPHERE; GFF MDI; Glycopyrrolate/formoterol; PT-003; PT001/PT005; PT003-GFF; PT005/PT001

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Jun 2018 Pearl Therapeutics completes a phase III trial in Chronic obstructive pulmonary disease in Japan (Inhalation) (NCT03262012)
  • 04 May 2018 AstraZeneca completes the AERISTO trial in Chronic obstructive pulmonary disease in Bulgaria, Canada, France, Hungary, Russia, Ukraine, USA (Inhalation) (NCT03162055)
  • 02 Feb 2018 AstraZeneca announces intention to submit regulatory filings for Chronic obstructive pulmonary disease in Japan and China in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top